Publications by authors named "Iris Ballaouri"
Purpose: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent disease with limited treatment options. The aim of this study was to evaluate the preventive effects of a sodium-glucose co-transporter (SGLT)-2 inhibitor, empagliflozin, on a dietary mouse model of MASLD.
Methods: In total, 24 C57BL/6 J mice of both sexes were randomly allocated to three groups, as follows: the fast food diet (FFD) group (eight mice, receiving a high-fat, high-cholesterol, high-fructose diet, FFD), the EMPA group (eight mice, fed a FFD with 10 mg/kg/d empagliflozin), and the chow diet (eight mice, CD) group.
Purpose: The need to investigate the pathogenesis and treatment of nonalcoholic fatty liver disease (NAFLD) has led to the development of multiple mouse models. The aim of this study was to validate a fast food diet (FFD) mouse model that is introduced as being close to the human disease.
Methods: Eight to nine weeks old male and female C57BL/6 J mice were randomly allocated to a FFD group or to a chow diet (CD) group.
Article Synopsis
- Goserelin, a GnRH analog, induced menstrual cessation in premenopausal women, leading to significant reductions in bone mineral density (BMD) at both lumbar spine and femoral neck after 6 months.
- After 6 months of menstrual restoration, lumbar spine BMD showed some recovery but remained lower than baseline levels, while femoral neck BMD stayed stable. Bone turnover markers initially increased but decreased again by the 12-month mark.
- Changes were noted in specific circulating microRNAs related to bone metabolism, with significant downregulation at 6 months and a robust increase in expression at 12 months, suggesting altered bone remodeling processes.
An acute phase response (APR) is frequently observed in patients treated with intravenous (i.v.) zoledronate (ZOL).
View Article and Find Full Text PDFUnlabelled: Objective To evaluate the effect of strontium ranelate (SR) on bone turnover markers in women with established osteoporosis previously treated with teriparatide (TPTD--recombinant human PTH 1-34). DESIGN PATIENTS: Twenty-two postmenopausal Caucasian women (aged 65.7 +/- 1.
View Article and Find Full Text PDF